Exploration of 2-Mercaptoquinazolin-4(3H)-one Based N-Hydroxyheptanamides as Histone Deacetylase Inhibitors: Design, Synthesis, and Anticancer Bioevaluation

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Pharmaceutical Research

• Publication date

  2025-11-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s11095-025-03928-xPMID 41219568
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer epigenetics: from laboratory studies and clinical trials to precision medicine

  2024cited by this paper
• HDAC-targeting epigenetic modulators for cancer immunotherapy.

  2024cited by this paper
• Novel quinazolin-4-one based derivatives bearing 1,2,3-triazole and glycoside moieties as potential cytotoxic agents through dual EGFR and VEGFR-2 inhibitory activity

  2024cited by this paper
• Design, synthesis, and antiproliferative activity of new 1,2,3-triazole/quinazoline-4-one hybrids as dual EGFR/BRAFV600E inhibitors

  2024cited by this paper
• Discovery of novel 2-substituted 2, 3-dihydroquinazolin-4(1H)-one derivatives as tubulin polymerization inhibitors for anticancer therapy: The in vitro and in vivo biological evaluation.

  2024cited by this paper
• 6-Bromo quinazoline derivatives as cytotoxic agents: design, synthesis, molecular docking and MD simulation

  2024cited by this paper
• Design, Synthesis, Pharmacological Evaluation of Quinazolin-4(3H)-Ones Bearing Urea Functionality as Potential VEGFR-2 Inhibitors

  2024cited by this paper
• 2,3-Dihydroquinazolin-4(1H)-ones and quinazolin-4(3H)-ones as broad-spectrum cytotoxic agents and their impact on tubulin polymerisation.

  2024cited by this paper
• Design, synthesis, molecular docking, and in vitro studies of 2-mercaptoquinazolin-4(3H)-ones as potential anti-breast cancer agents

  2024cited by this paper
• Dysregulation of different modes of programmed cell death by epigenetic modifications and their role in cancer.

  2024cited by this paper
• Recent histone deacetylase inhibitors in cancer therapy

  2023cited by this paper
• Synthesis and antibacterial activities of some novel hybrid compounds based on 2‐mercapto‐3‐arylquinazolin‐4(3H)‐one scaffold bearing specific coumarin

  2023cited by this paper
• Synthesis and Evaluation of Novel Quinazolinone Thioether Linked 5-Aryl-1,2,4-Triazoles for Anticancer and Antimicrobial Activity

  2023cited by this paper
• Epigenetics: Mechanisms, potential roles, and therapeutic strategies in cancer progression

  2023cited by this paper
• Design and synthesis of novel quinazolinone-based derivatives as EGFR inhibitors with antitumor activity

  2022cited by this paper
• Green Process for the Synthesis of 3-Amino-2-methyl-quinazolin-4(3H)-one Synthones and Amides Thereof:DNA Photo-Disruptive and Molecular Docking Studies

  2022cited by this paper
• Structure-based design, synthesis and antiproliferative action of new quizoline-4-one/chalcone hybrids as EGFR inhibitors

  2022cited by this paper
• HDAC Inhibitors: Dissecting Mechanisms of Action to Counter Tumor Heterogeneity

  2021cited by this paper
• Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy.

  2021cited by this paper
• Strategies To Design Selective Histone Deacetylase Inhibitors

  2021cited by this paper
• Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives

  2021cited by this paper
• Novel 4-Oxoquinazoline-Based N-Hydroxypropenamides as Histone Deacetylase Inhibitors: Design, Synthesis, and Biological Evaluation

  2021cited by this paper
• Design and synthesis of novel quinazolinone‐based fibrates as PPARα agonists with antihyperlipidemic activity

  2021cited by this paper
• Quinazolin-4(3H)-one based potential multiple tyrosine kinase inhibitors with excellent cytotoxicity

  2021cited by this paper
• Design, Synthesis and Evaluation of Novel Indirubin-based N-Hydroxybenzamides, N-Hydroxypropenamides and N-Hydroxyheptanamides as Histone Deacetylase Inhibitors and Antitumor Agents.

  2020cited by this paper
• Design, synthesis and in vitro biological evaluation of quinazolinone derivatives as EGFR inhibitors for antitumor treatment

  2020cited by this paper
• Design, synthesis, biological evaluation of 6-(2-amino-1H-benzo[d]imidazole-6-yl)quinazolin-4(3H)-one derivatives as novel anticancer agents with Aurora kinase inhibition.

  2020cited by this paper
• Hydroxamic acid hybrids as the potential anticancer agents: An Overview.

  2020cited by this paper
• Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)

  2020cited by this paper
• 4-(3H)-quinazolinones N-3 substituted with a five membered heterocycle: A promising scaffold towards bioactive molecules.

  2020cited by this paper
• Novel 3,4-dihydro-4-oxoquinazoline-based acetohydrazides: Design, synthesis and evaluation of antitumor cytotoxicity and caspase activation activity.

  2019cited by this paper
• Design, synthesis, molecular modeling, in vivo studies and anticancer evaluation of quinazolin-4(3H)-one derivatives as potential VEGFR-2 inhibitors and apoptosis inducers.

  2019cited by this paper
• Quinazolin‐4(3H)‐one‐Based Hydroxamic Acids: Design, Synthesis and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity

  2019cited by this paper
• Design, synthesis and evaluation of novel N-hydroxybenzamides/N-hydroxypropenamides incorporating quinazolin-4(3H)-ones as histone deacetylase inhibitors and antitumor agents.

  2018cited by this paper
• Quinazoline‐Based Hydroxamic Acids: Design, Synthesis, and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity

  2018cited by this paper
• Design, Synthesis, and Biological Evaluation of Mitochondria-Targeted Flavone-Naphthalimide-Polyamine Conjugates with Antimetastatic Activity.

  2017cited by this paper
• Facile access to potent antiviral quinazoline heterocycles with fluorescence properties via merging metal-free domino reactions

  2017cited by this paper
• Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2-a]pyridine and quinazolin-4(3H)-one derivatives as PI3Kα inhibitors.

  2017cited by this paper
• Quinazolinone and quinazoline derivatives: recent structures with potent antimicrobial and cytotoxic activities

  2016cited by this paper
• Synthesis, molecular structure and spectroscopic studies of some new quinazolin-4(3H)-one derivatives; an account on the N- versus S-Alkylation

  2016cited by this paper
• Synthesis, molecular modeling, and biological evaluation of quinazoline derivatives containing the 1,3,4-oxadiazole scaffold as novel inhibitors of VEGFR2

  2015influential reference
• Synthesis, biological evaluation and molecular modeling study of 2-(1,3,4-thiadiazolyl-thio and 4-methyl-thiazolyl-thio)-quinazolin-4-ones as a new class of DHFR inhibitors.

  2014cited by this paper
• A structural insight into hydroxamic acid based histone deacetylase inhibitors for the presence of anticancer activity.

  2013cited by this paper
• Synthesis, Antimicrobial, and Anti-HIV1 Activity of Quinazoline-4(3H)-one Derivatives

  2013cited by this paper
• Design, synthesis, and structure-activity relationships of novel 6,7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents.

  2013cited by this paper
• Kinetics and docking studies of two potential new inhibitors of the nucleoside hydrolase from Leishmania donovani.

  2012cited by this paper
• HDACi

  2011cited by this paper
• Zinc chelation with hydroxamate in histone deacetylases modulated by water access to the linker binding channel.

  2011cited by this paper
• Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones

  2010cited by this paper
• Nonclinical Safety Assessment of the Histone Deacetylase Inhibitor Vorinostat

  2010cited by this paper
• Synthesis and evaluation of 4-quinazolinone compounds as potential antimalarial agents.

  2010cited by this paper
• Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma

  2007cited by this paper
• Prediction of protein-ligand interactions. Docking and scoring: successes and gaps.

  2006cited by this paper
• Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors

  1999cited by this paper
• Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening.

  1992cited by this paper

• Novel 2-mercaptoquinazolinone N-hydroxycinnamamides as histone deacetylase inhibitors: design, synthesis, and anticancer evaluation.

  2025cites this paper